Back

Study protocol for a randomized clinical pilot trial investigating feasibility and efficacy of augmenting a virtual reality-assisted intervention targeting auditory verbal hallucinations with biofeedback: the Neuro-VR study

Soleim, S. B.; Habla, A. F.; Due, A. S.; Tinglef, T. H.; Eskelund, K.; Diaz-i-Calvete, J.; Larsen, K. M.; Kristensen, T. D.; Ebdrup, B. H.; Nordentoft, M.; Lyngholm, D.; Miskowiak, K. W.; Ambrosen, K. S.; Birkedal Glenthoj, L.

2025-09-21 psychiatry and clinical psychology
10.1101/2025.09.19.25336131
Show abstract

IntroductionAuditory Verbal Hallucinations (AVH) are among the most frequent and severe symptoms in schizophrenia and related psychotic disorders. Virtual Reality (VR)-assisted interventions have emerged, demonstrating promising potential in reducing AVH severity. This treatment approach may be challenged with regards to feasibility, particularly when therapeutically managing the anxiety-related reactions associated with AVH. This pilot study evaluates the feasibility and acceptability of augmenting VR-assisted therapy with real-time biofeedback to address these challenges. The integration of biofeedback enables continuous adaptation of therapy based on physiological responses while allowing participants to train self-regulation of these parameters. MethodsNeuro-VR is a randomized clinical pilot trial utilizing a mixed-methods design. Thirty participants with schizophrenia spectrum disorders and AVH will be randomized to either eight sessions of VR-assisted therapy or eight sessions of VR-assisted therapy augmented with real-time biofeedback. Assessments will be conducted at baseline and post-treatment. Outcome measures include both clinical metrics, electroencephalogram recordings, and qualitative interviews to evaluate feasibility, acceptability, and potential treatment effects of the combined approach. DiscussionThis study will explore whether integrating biofeedback into VR-assisted therapy enhances personalization, supports emotion regulation, and improves tolerability. The findings will provide preliminary evidence on the utility of physiological markers to guide VR-based interventions for AVH and inform the development of individualized, effective treatments for patients with schizophrenia. Trial registrationClinicalTrials.gov, NCT06628323 (https://clinicaltrials.gov/study/NCT06628323). Registered August 19, 2024.

Matching journals

1
Schizophrenia
Springer Science and Business Media LLC · based on 13 published papers
#1
189× avg
2
Schizophrenia Bulletin
Oxford University Press (OUP) · based on 21 published papers
Top 0.4%
78× avg
3
Schizophrenia Research
Elsevier BV · based on 11 published papers
#1
192× avg
4
PLOS ONE
Public Library of Science (PLoS) · based on 1737 published papers
Top 58%
7.5%
5
Frontiers in Psychiatry
Frontiers Media SA · based on 56 published papers
Top 2%
16× avg
6
Psychological Medicine
Cambridge University Press (CUP) · based on 52 published papers
Top 2%
14× avg
7
JMIR Formative Research
JMIR Publications Inc. · based on 31 published papers
Top 0.9%
21× avg
8
Journal of Psychiatric Research
Elsevier BV · based on 22 published papers
Top 0.3%
55× avg
9
Psychiatry Research
Elsevier BV · based on 33 published papers
Top 2%
15× avg
10
Translational Psychiatry
Springer Science and Business Media LLC · based on 94 published papers
Top 5%
5.4× avg
11
Biological Psychiatry
Elsevier BV · based on 36 published papers
Top 2%
11× avg
12
Journal of Medical Internet Research
JMIR Publications Inc. · based on 81 published papers
Top 8%
2.6× avg
13
BMC Psychiatry
Springer Science and Business Media LLC · based on 20 published papers
Top 1%
19× avg
14
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
Elsevier BV · based on 27 published papers
Top 2%
12× avg
15
JAMA Psychiatry
American Medical Association (AMA) · based on 11 published papers
Top 0.5%
32× avg
16
The British Journal of Psychiatry
Royal College of Psychiatrists · based on 21 published papers
Top 2%
9.6× avg
17
Scientific Reports
Springer Science and Business Media LLC · based on 701 published papers
Top 80%
1.2%
18
Neuroscience & Biobehavioral Reviews
Elsevier BV · based on 19 published papers
Top 3%
11× avg
19
Journal of Affective Disorders
Elsevier BV · based on 72 published papers
Top 5%
3.0× avg
20
NeuroImage: Clinical
Elsevier BV · based on 77 published papers
Top 7%
2.0× avg
21
npj Digital Medicine
Springer Science and Business Media LLC · based on 85 published papers
Top 13%
0.8%
22
Neuropsychopharmacology
Springer Science and Business Media LLC · based on 29 published papers
Top 3%
6.6× avg
23
JMIR Research Protocols
JMIR Publications Inc. · based on 18 published papers
Top 3%
5.4× avg
24
Brain Stimulation
Elsevier BV · based on 27 published papers
Top 2%
6.6× avg
25
International Journal of Environmental Research and Public Health
MDPI AG · based on 116 published papers
Top 25%
0.7%
26
European Neuropsychopharmacology
Elsevier BV · based on 11 published papers
Top 2%
11× avg
27
Molecular Psychiatry
Springer Science and Business Media LLC · based on 84 published papers
Top 7%
2.5× avg
28
Frontiers in Neurology
Frontiers Media SA · based on 74 published papers
Top 13%
0.7%
29
BMJ Open
BMJ · based on 553 published papers
Top 53%
0.7%
30
European Journal of Neuroscience
Wiley · based on 10 published papers
Top 0.8%
18× avg